[61] found the expression of B7‐H4 in ovarian cancer patients with resistant to platinum and PARPi, and further animal experiments demonstrated that B7‐H4 antibody–drug conjugates (ADCs) can inhibit the growth of B7‐H4‐positive tumors. Here, VTCN1 is linked to ovarian carcinoma.